TitleLSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
Publication TypeJournal Article
Year of Publication2018
AuthorsSehrawat, A, Gao, L, Wang, Y, Bankhead, A, McWeeney, SK, King, CJ, Schwartzman, J, Urrutia, J, Bisson, WH, Coleman, DJ, Joshi, SK, Kim, D-H, Sampson, DA, Weinmann, S, Kallakury, BVS, Berry, DL, Haque, R, Van Den Eeden, SK, Sharma, S, Bearss, J, Beer, TM, Thomas, GV, Heiser, LM, Alumkal, JJ
JournalProc Natl Acad Sci U S A
Date Published2018 Mar 26

Medical castration that interferes with androgen receptor (AR) function is the principal treatment for advanced prostate cancer. However, clinical progression is universal, and tumors with AR-independent resistance mechanisms appear to be increasing in frequency. Consequently, there is an urgent need to develop new treatments targeting molecular pathways enriched in lethal prostate cancer. Lysine-specific demethylase 1 (LSD1) is a histone demethylase and an important regulator of gene expression. Here, we show that LSD1 promotes the survival of prostate cancer cells, including those that are castration-resistant, independently of its demethylase function and of the AR. Importantly, this effect is explained in part by activation of a lethal prostate cancer gene network in collaboration with LSD1's binding protein, ZNF217. Finally, that a small-molecule LSD1 inhibitor-SP-2509-blocks important demethylase-independent functions and suppresses castration-resistant prostate cancer cell viability demonstrates the potential of LSD1 inhibition in this disease.

Alternate JournalProc. Natl. Acad. Sci. U.S.A.
PubMed ID29581250